In November 2018, Chinese scientist He Jiankui stunned the world by announcing that he had created the first genetically edited babies. The claim was made at a conference in Hong Kong, where He presented twin girls—later nicknamed “Lulu” and “Nana”—as proof of concept for using CRISPR to alter the human genome before birth. The revelation sparked immediate outrage, not only because it involved children who could never consent, but also because it crossed a line that many bioethicists believed should remain firmly closed.
The technology at the heart of He’s experiment, CRISPR, originated from a bacterial immune system that captures snippets of viral DNA and uses them to recognize future infections. In the laboratory, scientists repurpose this system by designing a short RNA guide that leads the Cas9 enzyme to a precise genomic location, where it creates a double‑strand break. The cell’s own repair machinery then stitches the DNA back together, often introducing small insertions or deletions that can disrupt a gene’s function. This simplicity and precision made CRISPR an instant sensation across genetics, agriculture, and medicine.
A crucial distinction in genome editing is between germline editing and somatic cell interventions. Somatic edits treat diseases in the individual receiving them—think of a gene therapy that corrects a faulty allele in liver cells. Germline edits, by contrast, alter the DNA of an egg, sperm, or early embryo, meaning any changes become part of every cell in the resulting person and can be inherited by future generations. He’s work fell squarely into the latter category, raising concerns about unintended consequences that could ripple through the human gene pool.
He targeted the CCR5 gene, which encodes a receptor that HIV uses to enter immune cells. By disabling CCR5, he hoped to confer resistance to HIV infection—a noble goal in theory, but one fraught with technical risk. Early‑stage embryos were edited, then implanted into He’s wife’s uterus. The twins were born in 2019, reportedly healthy at birth, yet independent verification of the edits proved impossible because the family refused further testing. Moreover, scientists warned about off‑target effects and unknown impacts on embryonic development, which could manifest later in life or be passed to descendants.
The global reaction was swift. The World Health Organization convened an expert panel, UNESCO issued a declaration on the “human genome,” and numerous national academies called for a moratorium on clinical germline editing. Central to the debate were questions of bioethics, informed consent, and equitable access. Critics argued that He’s work violated both Chinese regulations—though loopholes existed—and international norms that emphasize transparency, peer review, and rigorous safety testing before any human application.
In the aftermath, Chinese authorities sentenced He to three years in prison for “illegal medical practices” and imposed a fine. The incident prompted China to draft stricter laws governing gene editing, explicitly banning clinical germline modifications. Internationally, the episode accelerated discussions within bodies such as the International Commission on the Clinical Use of Human Germline Genome Editing, which released detailed guidelines outlining permissible research, oversight mechanisms, and public engagement strategies.
Today, while no laboratory is implanting edited embryos into humans, researchers continue to use CRISPR in embryo models for disease modeling and drug discovery. The scientific community remains divided: some argue that a carefully regulated, transparent pathway could eventually allow therapeutic germline edits for severe monogenic diseases; others maintain that the societal risks outweigh potential benefits. He Jiankui’s controversial experiment thus serves as both a cautionary tale and a catalyst, reminding us that powerful technologies demand equally robust ethical frameworks.